Original paper
Treatment with Nusinersen – Challenges Regarding the Indication for Children with SMA Type 1
Abstract
The natural history of patients with spinal muscular atrophy (SMA) has changed due to advances in standard care and development of targeted treatments. Nusinersen was the first drug approved for the treatment of all SMA patients. The transfer of clinical trial data into a real-life environment is c hallenging, especially regarding the advice of patients and families to what extent they can expect a benefit from the novel treatment. We report the...
Paper Details
Title
Treatment with Nusinersen – Challenges Regarding the Indication for Children with SMA Type 1
Published Date
Jan 22, 2020
Volume
7
Issue
1
Pages
41 - 46
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History